Art. -Nr.: HY-13260

CCT128930

7 Cited Publications

Kundenbewertung

Based on 7 publication(s) in Google Scholar

CCT128930 is a ATP-competitive and selective inhibitor of AKT (IC₅₀=6 nM for AKT2). CCT128930 has 28-fold selectivity over the closely related PKA kinase (IC₅₀=168 nM) through the targeting of Met282 of AKT (Met173 of PKA-AKT chimera), as well as 20-fold selectivity over p70S6K (IC₅₀=120 nM). Antitumor activity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.95%
CAS. Nr.: 885499-61-6
Formel: C₁₈H₂₀ClN₅
Molecular Weight:341.84

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

CCT128930 Chemical Structure

CAS. Nr.: 885499-61-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (7)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

Akt2

6 nM (IC₅₀)

p70S6K

120 nM (IC₅₀)

PKA

168 nM (IC₅₀)

Autophagy

Apoptosis

Alle Akt Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
PC-3M	GI₅₀	12 nM Compound: 2, CCT128930	Antiproliferative activity against human PC3M cells after 96 hrs by SRB assay Antiproliferative activity against human PC3M cells after 96 hrs by SRB assay	[PMID: 20151677]
PC-3M	IC₅₀	0.66 μM Compound: 25	Inhibition of PIK-PKB-mTOR pathway in human PC3M cells Inhibition of PIK-PKB-mTOR pathway in human PC3M cells	[PMID: 18345609]
PC-3M	IC₅₀	12 μM Compound: 25	Growth inhibition of human PC3M cells by SRB assay Growth inhibition of human PC3M cells by SRB assay	[PMID: 18345609]
U-87MG ATCC	GI₅₀	5 nM Compound: 2, CCT128930	Antiproliferative activity against human U87MG cells after 96 hrs by SRB assay Antiproliferative activity against human U87MG cells after 96 hrs by SRB assay	[PMID: 20151677]
U-87MG ATCC	GI₅₀	6.3 μM Compound: 14; CCT128930	Antiproliferative activity against human U87MG cells after 96 hrs by SRB assay Antiproliferative activity against human U87MG cells after 96 hrs by SRB assay	[PMID: 30583248]
U-87MG ATCC	IC₅₀	0.66 nM Compound: 2, CCT128930	Inhibition of PKB in human U87MG cells assessed as GSK3-beta phosphorylation by ELISA Inhibition of PKB in human U87MG cells assessed as GSK3-beta phosphorylation by ELISA	[PMID: 20151677]
U-87MG ATCC	IC₅₀	0.66 μM Compound: 25	Inhibition of GSK3-beta in human U87MG cells by ELISA Inhibition of GSK3-beta in human U87MG cells by ELISA	[PMID: 18345609]
U-87MG ATCC	IC₅₀	0.66 μM Compound: 25	Inhibition of PIK-PKB-mTOR pathway in human U87MG cells Inhibition of PIK-PKB-mTOR pathway in human U87MG cells	[PMID: 18345609]
U-87MG ATCC	IC₅₀	5 μM Compound: 25	Growth inhibition of human U87MG cells by SRB assay Growth inhibition of human U87MG cells by SRB assay	[PMID: 18345609]

In Vitro

The GI₅₀ values of CCT128930 for growth inhibition are 6.3 μM for U87MG human glioblastoma cells, 0.35 μM for LNCaP human prostate cancer cells, and 1.9 μM for PC3 human prostate cancer cells, all of which are PTEN-deficient human tumor cell lines^[1].
CCT128930 (0.1-60 μM; 1 hour; U87MG human glioblastoma cells) shows an initial induction of AKT phosphorylation at serine 473 up to 20 μM, followed by a decreased in phosphorylation at higher concentrations^[1].
CCT128930 inhibits direct substrates of AKT (Ser9 GSK3β, pThr246 PRAS40 and pT24 FOXO1/p32 FOXO3a) at ≥5 μM, and the downstream target, pSer235/236 S6RP at ≥ 10 μM, with generally constant levels of the respective total proteins and GAPDH^[1].
CCT128930 (18.9 μM; U87MG human glioblastoma cells) causes an increase in phosphorylation of pSer473 AKT after 30 minutes, which is sustained for 48 hours. Total AKT protein signal decreases gradually from 8 hours to 48 hours of treatment^[1].
CCT128930 (PTEN-null U87MG human glioblastoma cells; over a 24-hour time period) results in an increase in G0/G1 phase cells from 43.6% to 64.8% after 24 hours of treatment^[1].
CCT128930 (0-10 μM; 24 hours) increases, but not inhibites, the phosphorylation of Akt in HepG2 and A549 cells. CCT128930 (0-20 μM; 24 hours) inhibits cell proliferation by inducing cell cycle arrest in G1 phase through downregulation of cyclinD1 and Cdc25A, and upregulation of p21, p27 and p53. CCT128930 (20 μM) triggers cell apoptosis with activation of caspase-3, caspase-9, and PARP. CCT128930 (0-20 μM; 24 hours) increases phosphorylation of ERK and JNK in HepG2 cells. CCT128930 (0-20 μM; 24 hours) activates DNA damage response of HepG2 cell characterized by phosphorylation of H2AX, ATM (ataxia-telangiectasia mutated), Chk1 and Chk2^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

CCT128930 (25 or 40 mg/kg; i.p. daily or twice daily for 5 days) shows antitumor activities in U87MG and BT474 human breast cancer xenografts^[1].
Summary of the pharmacokinetic parameters of CCT128930 (25 mg/kg) in CrTacNCr-Fox1nu mice^[1]

Tissue	Route	T_1/2 (h)	T_max (h)	C_max (μM)	V_ss (L)	Cl (L/h)	AUC_0-∞ (µMh)	Bioavailability (%)
Plasma	i.v.	0.95	0.083	6.36	0.25	0.325	4.62	100
Plasma	i.p.	2.33	0.5	1.28	N/A	0.372	1.33	28.8
Tumor	i.p.	3.89	1	8.02	N/A	0.06^*	25.8	N/A
Plasma	p.o.	0.57	0.5	0.432	N/A	0.317	0.392	8.5

^*Apparent clearance.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

6-8 weeks old female CrTacNCr-Fox1nu mice^[1]
Dosage:

25 mg/kg (U87MG human glioblastoma xenografts) or 40 mg/kg (BT474 human breast cancer xenografts)
Administration:

i.p. daily for 5 days (U87MG human glioblastoma xenografts); i.p. twice daily for 5 days (BT474 human breast cancer xenografts)
Result:

Giving a treated:control (T/C) ratio on day 12 of 48%. There was no weight loss associated with this regime in U87MG human glioblastoma xenografts.
Had a profound antitumor effect with complete growth arrest and a T/C ratio of 29% on day 22. This regimen was associated with minimal weight loss, with a nadir of only 94.8% of the initial body weight on day 15 of treatment in BT474 human breast cancer xenografts.

Chemical Information

CAS. Nr. 885499-61-6
Appearance Solid
Molecular Weight 341.84
Formel C₁₈H₂₀ClN₅
Color Off-white to yellow
SMILES

ClC1=CC=C(C=C1)CC2(CCN(CC2)C3=NC=NC4=C3C=CN4)N
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (7)

All Bio/Physico-chemical AssayCell Proliferation/Viability AssayWBELISAIF

Sort by:

Journal Impact Factor

Cell Death Dis

PEBP4 alleviates muscle wasting in lung cancer cachexia via KEAP1-NRF2-mediated redox homeostasis. [Abstract]

2026 Jun 3. PMID: 42236665
J Transl Med

Trained immunity attenuated acute lung injury by activating alveolar macrophages via AKT2-PDK1 axis-mediated metabolic reprogramming. [Abstract]

2025 Dec 23;23(1):1412. PMID: 41437043

CCT128930 purchased from MedChemExpress. Usage Cited in: J Transl Med. 2025 Dec 23;23(1):1412. [Abstract]

Lactate secretion levels were measured following CCT128930 (CCT) treatment and compared with the TI group.

CCT128930 purchased from MedChemExpress. Usage Cited in: J Transl Med. 2025 Dec 23;23(1):1412. [Abstract]

CCK-8 assay demonstrated reduced cellular lactate tolerance after CCT128930 (CCT) treatment.

CCT128930 purchased from MedChemExpress. Usage Cited in: J Transl Med. 2025 Dec 23;23(1):1412. [Abstract]

Western blot and QPCR analyses revealed decreased PDK1 and inflammatory marker expression after CCT128930 (CCT) treatment.

CCT128930 purchased from MedChemExpress. Usage Cited in: J Transl Med. 2025 Dec 23;23(1):1412. [Abstract]

TNF-α ELISA showed significant reduction after CCT128930 (CCT) treatment.

CCT128930 purchased from MedChemExpress. Usage Cited in: J Transl Med. 2025 Dec 23;23(1):1412. [Abstract]

CCT128930 (CCT) treatment impaired phagocytic capacity.
Mol Cancer Ther

AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer. [Abstract]

2024 Oct 1;23(10):1404-1417. PMID: 38894678
Biochem Biophys Res Commun

CCT128930 is a novel and potent antagonist of TRPM7 channel. [Abstract]

2021 Jun 30:560:132-138. PMID: 33989904
Patent

US20240066113A1.
J Healthc Eng

Study on Toll-Like Receptor 2-Mediated Inflammation-Induced Familial Hypertension Combined with Hyperlipemia and Its Mechanism. [Abstract]

2022 Jan 5:2022:1473597. PMID: 35035808
Oncotarget

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML. [Abstract]

2016 May 17;7(20):29131-42. PMID: 27074558

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 33.33 mg/mL (97.50 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9253 mL

14.6267 mL

29.2535 mL

5 mM

0.5851 mL

2.9253 mL

5.8507 mL

10 mM

0.2925 mL

1.4627 mL

2.9253 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (6.08 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (6.08 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (6.08 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Yap TA et al. Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930. Mol Cancer Ther. 2011 Feb;10(2):360-71. [Content Brief]

[2]. Wang FZ, et al. CCT128930 induces cell cycle arrest, DNA damage, and autophagy independent of Akt inhibition. Biochimie. 2014;103:118-125. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9253 mL	14.6267 mL	29.2535 mL	73.1336 mL
	5 mM	0.5851 mL	2.9253 mL	5.8507 mL	14.6267 mL
	10 mM	0.2925 mL	1.4627 mL	2.9253 mL	7.3134 mL
	15 mM	0.1950 mL	0.9751 mL	1.9502 mL	4.8756 mL
	20 mM	0.1463 mL	0.7313 mL	1.4627 mL	3.6567 mL
	25 mM	0.1170 mL	0.5851 mL	1.1701 mL	2.9253 mL
	30 mM	0.0975 mL	0.4876 mL	0.9751 mL	2.4378 mL
	40 mM	0.0731 mL	0.3657 mL	0.7313 mL	1.8283 mL
	50 mM	0.0585 mL	0.2925 mL	0.5851 mL	1.4627 mL
	60 mM	0.0488 mL	0.2438 mL	0.4876 mL	1.2189 mL
	80 mM	0.0366 mL	0.1828 mL	0.3657 mL	0.9142 mL

CCT128930

7 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

CCT128930

Apoptosis Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Targeted Diversity Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) CCT128930

Alle Akt Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (7)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

CCT128930 Related Classifications

HY-13260 Related Classifications